Page 11234..1020..»

Archive for the ‘Regenerative Medicine’ Category

Seven Stories of Regeneration | Tufts Now – Tufts Now

Thursday, December 17th, 2020

In this episode, were all about regeneration. We talk with a Tufts biologist about the ways some animals regrow lost body parts, and the real possibility of science helping humans do the same one day. An ecologist explains how forests have the capacity to recover from even the most devastating wildfiresan ability theyve honed over thousands of years.

We hear how some species have come back from near extinction with a little attention from their human counterparts, and some enthusiastic farmers show that even something as basic as dirt can come alive with the right care. We share one experts vision for growing a better, greener economy in the wake of the pandemic, before taking a detour for the tale of some long-lost paintings given a second chance for appreciation.

Finally, we talk with an alumna who suffered a great physical loss, but went on to build a new career and a new outlook for herself. As she says, Theres always an opportunity for renewal.

Subscribe toTell Me MoreonApple Podcasts,Google Play Music,Spotify,Stitcher, andSoundCloud.

Read the Full Transcript

Read More About Regenerative Medicine

Michael Levin, A92, is the director of the Allen Discovery Center at Tufts University and the Tufts Center for Regenerative and Developmental Biology. He is also Vannevar Bush Professor and Distinguished Professor of Biology. Read about frogs starting to regrow limbs, tadpoles prompted to grow extra eyes, and some other recent research from his lab on Tufts Now.

Michael Reed, professor of biology, studies avian ecology and conservation biology. He looks at how habitat loss and fragmentation affect extinction risk and population viability, as well as the role of animal behavior in extinction risk and conservation.To get a feel for why species regeneration is so urgent, read about the UN report on species extinction rates, the report on species population size decline, and the 3 billion North American birds that have vanished since 1970.

Erica Smithwick, J95, majored in geology and environmental studies at Tufts. She is now a professor of geography at Penn State, where she is director of the Ecology Institute. A landscape and ecosystem ecologist, she is involved in understanding how a wide range of disturbances, especially fire, affect ecosystem function.

Rachel Kyte is the dean of The Fletcher School. A 2002 graduate ofFletchers Global Master of Arts program, Kyte served as special representative of the UN secretary-general and chief executive officer ofSustainable Energy for All. Previously, she was the World Bank Group vice president and special envoy for climate change. Read more about her call for a green recovery in the New York Times.

Meghan Powers and Elliot Rossow started their cultivation careers through a course with the New Entry Sustainable Farming Project at the Friedman School of Nutrition Science and Policy, later applying for a plot of land through NESFPs incubator program. They now run Kona Farms as a living laboratory for environmental stewardship. Reach them at konafarmsma@gmail.com or on Instagram.

Christina Maranci is chair of the department of history of art and architecture in the School of Arts and Sciences. She is also the Arthur H. Dadian and Ara Oztemel Professor of Armenian Art and Architecture. Maranci's research is mainly onmedieval Armenian history and the relationship with the Sasanian, Byzantine, and Islamic empires. See some of her photos of the art of Ani Cathedral on Tufts Now.

Maggie Baumer, A04, studied clinical psychology at Tufts before graduating from law school. She manages the Springfield, Mass., location of Hanger Clinic, the nations largest provider of state-of-the-art prostheses. She is also a certified peer visitor for theAMPOWER program, a peer-to-peer network designed to empower and strengthen those affected by amputation or limb difference.

Transcript

JULIE FLAHERTY: 2020 has been a really rough year, which is why everyone is hoping that a new year will bring brighter times.

ANNA MILLER: And that got us thinkingabout renewal, about starting over, about rising from the ashes. This is Tell Me More, the Tufts University podcast. Im Anna Miller.

FLAHERTY: And Im Julie Flaherty. In this episode, were all about regeneration. Were talking forests that bounce back after massive wildfires, animals that regrow lost limbs, and people who manage to rebuild their lives after calamity.

MILLER: They are just the kind of inspiring stories we need right now.

FLAHERTY: If you want to be encouraged about the possibility of regeneration, just talk to Michael Levin. Levin is the director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. I asked him about the most impressive examples of regeneration he knows.

MICHAEL LEVIN: Many people know about things like the axolotl, which is a salamander that will regenerate almost any organ. So they regenerate their eyes, their jaws, their limbs, their ovaries, portions of their brain and heart. But some other cool ones are, for example, deer. So deer are a large adult mammal, and every year they regenerate their antlers. And antlers have bone and skin and vasculature and nerve, and they will regenerate those antlers at a rate of about a centimeter and a half per day. So think about that. Every day, that thing adds a centimeter and a half of new bone.

FLAHERTY: But even more impressive might be a creature Levin uses in a lot of his worka little guy called the flatworm.

LEVIN: Well, the planaria, the flatworms are an amazing model system. They combine most of the interesting problems of biology are found in this animal. Its just remarkable. First of all, they regenerate from any piece of the body. The record, I think is something like 275 pieces. You can cut the worm in any way you want. Every piece knows exactly what a correct worm looks like, and it will build exactly whats needed, no more, no less, to give you a tiny, perfect little worm. So they hold the secret to regeneration. So thats the first thing.

The second thing is theyre also immortal. They have no lifespan limits. So theres no such thing as an old planarian. They live forever, and thats telling us that in fact aging is not an inescapable part of life. These animals have been with us for probably 400 million years. And these are the exact same worms. They just do not age. So thats telling us that immortality is possible for a complex creature.

FLAHERTY: Thats all very well for the worms. But what about people?

LEVIN: The other thing a lot of people may not know is that even human children can regenerate their fingertips. So somewhere between the age of 7 and 11, most of us lose this. There used to be more of this back in the 70s, when fans werent covered with the metal grates and everything. But a clean amputation of a digit for a small child usually just grows back perfectly.

FLAHERTY: No one knows for sure why we lose the ability to regenerate as we get older. But Levin says that all of the information for how to do it is still inside us. We just need to figure out how to turn it back on. And Levin thinks it has something to do with bioelectricity, the flow of ions between cells in the body. Thats how cells communicate with each other.

Levin, who studied both biology and computer science as an undergrad at Tufts, likens it to software. If we can find the code that the cells use to communicate about regeneration, we can run that program, and get the cells to do the work of building a new finger or what have you.

LEVIN: So all of those kinds of computations, when the cells join together to say, what should we be building? Are we done yet? Is there a finger missing? How many fingers should there be? That kind of thing. All of that is mediated electrically.

So if we understood how that worked, we could artificially inject electrical information to get the cells to do whatever we wanted them to do. And so this means kickstart a normal regenerative cascade, or reprogram a tumor into normal tissues, or build a completely new anatomical structure thats never been seen before, some sort of synthetic living device. All of that is possible if we understand how cells cooperate towards these kinds of outcomes.

What weve developed are some of the first tools to listen in on, and then modify, the natural electrical conversations that cells are having with each other. We basically go in and we open and close the ion channels that are in those cells, to modify how they talk to each other.

FLAHERTY: Levins lab has conducted many groundbreaking experiments over the years. They have coaxed a mature frog, which typically does not have the ability to regenerate its limbs, to begin to grow a new leg. Another experiment involved convincing a tadpole to grow an eye. But they didnt want the eye in the usual place.

LEVIN: We observed that there was a special electrical pattern that was present in the embryo where the eye was going to form. So what we simply did was reproduce that same pattern somewhere else. What we found is that, sure enough, the cells know that that pattern means make an eye here. And if you make that electrical distribution in the gut, then you will have an eye in the gut, and if you make it in the tail, you will have an eye in the tail.

FLAHERTY: Yes, a tadpole with eyes on its tail is weird, but it showed something important. To use that software analogy again, it showed that cells can be reprogrammed. You dont have to rewire the hardware to make an eye.

LEVIN: We dont know how to make an eye ourselves. The eye has many different cell types, arranged in a really exquisite pattern. We cant reproduce any of that by hand. Its way too complex. But we found that with a very simple trigger, the whole eye is formed. So that told us that theres a path towards regenerative medicine where you dont need to try to micromanage the whole process. You need to find the logic of the natural software thats being used, and you can take advantage of it.

FLAHERTY: Levin believes that one day, humans are going to be able to regrow eyes, limbs, hearts, and other useful things.

And you think youre going to see this happen in your lifetime?

LEVIN: I hope I not only to see it happen, I hope I help make it happen. Were working very hard towards this now. Im optimistic. I think were going to see amazing things out of regenerative medicine in the next decade or two.

MILLER: So some animals are pretty good at regenerating body parts. But what happens when a whole group of animals is threatened with extinction? Is there any way to regrow a species? We put that question to someone who studies animal populations.

MICHAEL REED: My name is Michael Reed, Im a professor in the biology department at Tufts University.

MILLER: There is an urgency behind this question. Right now, were in an environmental crisis. And a lot of animals are disappearing.

REED: Were now moving into a sixth mass extinction thats, if continued, would build to be similar to one of the mass extinctions during geologic time, the last of which was the disappearance of most of the dinosaurs.

MILLER: This time, theres no meteor. Instead, its us. Simply put, our actions are killing animals around the globe in shocking numbers. Since the 1970s, 68 percent of all animal populations have been wiped out.

REED: If you were paying attention to the news a year ago, you would have seen around the world headline news of 3 billion birds lost in North America.

MILLER: A report delivered by the United Nations estimates that within the next 30 years, anywhere from a third to half of all species on the planet might go extinct. So what are humans doing to cause this? Its climate change, its wildlife trafficking, its use of pesticidesbut the biggest killer, says Reed, these animals have run out of places to live.

REED: The number one problem globally is habitat loss, habitat fragmentation, and degradation of habitat. If you take away a species habitat, the species doesnt exist anymore.

MILLER: So can we even turn this around? I asked Reed if he knows of a species that people have successfully brought back from the brink of extinction.

REED: Yeah. Fortunately there are examples, otherwise I think people would give up in despair.

We kept bison from going extinct in the U.S. Theyre not anywhere near the numbers they were at one time. There used to be hundreds of millions of them and their range actually extended into the middle of New York state. In Pennsylvania you could see bison. Their numbers are extremely low compared to that. But since we were down to dozens, I think the tens of thousands we have now is pretty good. So at that stage, it depends on exactly how youre defining success.

MILLER: When we stopped using the pesticide DDT, which turned out to be damaging to eggs, some bird species bounced back.

REED: The bald eagle has moved off of the endangered species list. The peregrine falcon has moved off the endangered species list. Osprey are returning to many of their haunts on the East Coast of the U.S. and Northern Europe with the cessation of the use of DDT.

Ironically, the one large group of birds thats doing really well, and their numbers are going up instead of down, is waterfowl. And we hunt them. Animals were going out and shooting, harvesting, their numbers are going up, while the animals that were not harvesting are going down. The big difference is for harvested animals, people are putting their money where their mouth is and says, Id like more of them. Lets spend millions of dollars recreating habitat, bolstering populations.

Frankly, any of you who go to national wildlife refuges, those were paid for by duck hunters. Thats why we have these refuges. It demonstrates that with interest and money, we can turn these around really well, even for harvested things. Looking at examples like that gives me a lot of hope.

MILLER: There are simple things people can do to boost wildlife populations.

REED: So if youre cutting down lots of habitat and the species are disappearing, quit wrecking so much habitat, or find ways to leave patches behind that are sufficient for species or corridors that connect one reserve to another reserve. Or in your yard, instead of having a bunch of grass, let some wildflowers grow and bring back native pollinators.

We have proven that we have the capacity to make a difference and to turn things around and that it just requires some awareness and some thoughtfulness.

FLAHERTY: We humans can take all the blame for habitat loss. But sometimes destruction and regeneration are just part of the natural cycle.

Erica Smithwick has made a career studying how ecosystems recover from traumas like insect infestations and wildfires. Smithwick, who graduated from Tufts in 1995 and is now a professor of geography at Penn State, has extensively studied the 1988 wildfires in Yellowstone National Park. More than 40 percent of the park was burned, and news accounts at the time made it seem like the park might not survive.

NEWS ANCHOR: Our oldest National Park is under siege tonight...

NEWS ANCHOR #2: The president to declare Yellowstone National Park a national disaster area...

ERICA SMITHWICK: The media coverage at the time was really alarmist. It was talking about the destruction and all these D words, death, destruction, disaster. It really was portrayed in that way. And actually what the science showed us was completely the opposite. And its one of the lessons we learned from studying the Yellowstone landscape over decades, frankly, is that the system recovered, it had the potential to recover.

And if you go to Yellowstone today, you probably wouldnt know that it once was a blackened landscape because its completely green, you see all of the trees coming back, a carpet of trees really just covering the whole landscape. And you have to dig deeper to understand that a lot of that regeneration was because the trees have the capacity to recover from severe fire.

FLAHERTY: In fact, the trees depend on fire to reproduce. They need the heat of a large fire to melt the resin in their pinecones and release seeds of new plants.

SMITHWICK: And it turns out that the lodgepole pine trees that are dominating a lot of the Yellowstone landscapes have this trait because they have adapted to severe fires over the past 10,000 years, the entire quaternary period. Theres memory in the system of these large wildfires. And the fires that occurred in 1988 were basically on cue.

It was about time for one of these large fires. Now, they dont come often, they come every 150 to 300 years. Thats why it wasnt part of our social memory of what the park should be experiencing. But within the context of what we can tell by paleo records of ash and pollen, this was fitting right in with a normal fire cycle of the park.

FLAHERTY: Almost as soon as the fires ended, seedling began to appear. Within a decade, trees rose up, and became what you see now as large mature trees. The recovery was also picturesque, as wildflowers took advantage of newfound sunlight.

SMITHWICK: Fireweed is a particular plant that is very beautiful. Its this purple-pink color and it just is covering the entire understory of the forest. And along with that comes the understory plants that bring nitrogen to the soil. This is a very impoverished nutrient poor ecosystem. And these understory plants bring a lot of nutrients back into the soil.

FLAHERTY Smithwicks research has shown that the fire itself brought a pulse of nitrogen to the soil, in part by breaking down organic matter on the forest floor, making nutrients for the next forest. And as Yellowstone came back, it came back different. Like aspen trees that sprang up where they hadnt been any before. In fact, fires are known for creating biodiversity.

SMITHWICK: Well, this is the thing about disturbances generally in forest city ecosystems is that they do create surprises. They create opportunities for new organisms to persist and even get reintroduced into a certain area.

There are a lot of birds that really enjoy post-fire landscapes or burned landscapes. So black-backed woodpecker would be one Kirtlands warbler in other parts of the U.S. A number of these birds will come into burned environments because the burned ecosystem has lots of cavity in the trees for nesting. And it also has a lot of bugs and beetles. The insects in that forest are actually just presenting a smorgasbord to sunbirds. The sunbirds, they depend on these burned ecosystems for survival, and will seek them out.

FLAHERTY: So forests can recover from massive wildfires. They just need time to do it. And its the lack of time that worries Smithwick right now. These big fires that usually happen hundreds of years apart are now happening every 15 or 30 years.

SMITHWICK: When we see fires like we have in the West, 8.6 million acres burned this year in 2020, and actually five times that amount in the Australian fires, just enormous areas burning. This is out of the realm of what we would expect to be normal. Thats concerning in terms of the ability of those forests to be able to recover.

We want an ecosystem that constantly is renewing itself. We have to learn to live with fire. And we all also have to learn to give our systems time to recover, because they have the capacity to do so.

There is nothing more important right now than fixing the climate situation. And so buying time to do that. And frankly, a lot of the climate work suggests that we do have the potential, if we make the right decisions now, to move the needle and that the earth system, the climate system, will actually respond very quickly.

MILLER: So forests can literally rise from the ashes, and often come back differentmaybe even better. Rachel Kyte, dean of The Fletcher School, thinks that the same is true for economies. Right now, in the midst of the pandemic, economies worldwide are hanging by a string. But Kyte is already thinking about the recovery, and the opportunity it presents to do something for the climate situation Smithwick was just talking about.

RACHEL KYTE: I think its really important to remember that before COVID hit, and I know that feels like a very long time ago, the economy wasnt working for everybody and it wasnt working for the planet.

When we think now about recovery, we have to recover, and through recovery, get ourselves on a trajectory for net-zero emissions by 2050. We have to recover clean and we have to recover in a way that we don't leave people behind. The good news is that thats entirely possible. They are not in opposition to each other.

MILLER: Kyte says that people are going to need jobs, and those jobs could easily be a part of building a greener economy.

KYTE: Whats been interesting through the pandemic is to see that we can agree, the economists worldwide, every international organization that we used to govern the global economy, that there are things that governments can do that will spur short-term income generation, short-term jobs, as well as mid-term growth and long-term emissions reduction.

For example, here in the Northeast of the United States, one of the most important things we could do is massively invest in programs to refurbish, deeply refurbish the built environment. Every time we make a building energy-efficient, those are good, local, skilled, and semi-skilled jobs, we reduce the emissions from this part of the United States, and we build our resilience to the next shocks.

We also know that investing in the infrastructure we need to drive electric cars and hydrogen fuel cells will be important. We also know that investing in the clean energy infrastructure that will allow us to use much more renewable energy will be important. These are good local jobs. Good, local jobs, well-paid put us on a better trajectory and put us on track for zero-net emissions.

MILLER: One way to help reduce carbon emissions is by fixing how we grow food. And thats where something called regenerative farming comes into play. Elliot Rossow is a soil microbiologist. And he cares so much about the earth, he can actually taste it.

ELLIOTROSSOW: Theres this entire classification system of soils and so I can grab some in my hand and put a little bit on my tongue and I can tell you, to a very specific content, how much sand, silt, and clay is in that soil. Which is awesome, its a great party trick.

MILLER:What does good soil taste like?

ROSSOW:Well, no soil really tastes good.

MILLER: Rossow and fellow soil-enthusiast Meghan Powers are incubator farmers with the New Entry Sustainable Farming Projectrun by the Friedman School of Nutrition Science and Policy.

They farm a small plot of land in Beverly, Massachusetts, where they groworganicvegetablesmost of which they donate to charity. But their real aim is figuring out how to bring life back to depleted soil.Heres Powers:

MEGHAN POWERS: So the main purpose of the farm is to test out new and really interesting sustainable management practices and sustainable inputs with the goal of regenerating the land and the soil itself.

MILLER: Why regenerate the land? Powers says the problem is that our agricultural system tends to treat soil like an inert thingput enough chemical fertilizers into it and plants will grow. But chemicals also break down the soil, degrading it. And over time, once you put in enough chemicals, the soil can become unusable.

POWERS:Its really important to start from this holistic perspective that we are working with the soil, and the soil is a living thing.

MILLER: Healthy soil is actually alive with active microbial communitiesmicrobes that help plants and make the soil more resilient. Rossow says you can actually see when dirt is thriving.

ROSSOW:You can definitely feel when soil is alive and intense, and if youve ever played in dirt, played in soil, you notice that it comes in different clumps. Theyre called aggregates, these big clods of dirt you see kids throwing at each other or people break it when they step on them.

But really, the more aggregates and the larger the aggregates means that theres more biological activity happening and flowing through that entire system. And so the more aggregates you have, and the healthier it is, you can see that they kind of grow in size. Whenever were soil sampling out there, and we find it, Oh, my gosh. Look at this one, its as big as my hand. Theyre massive.

MILLER: For the next three years, theyll be using their farm as a living laboratory, testing what works best to produce crops while still making the soil healthy. Because ultimately, healthy soil is a defense against climate change.

POWERS: And the great thing about soil is that you can regenerate it, you can build it back up, its not one and done, you can put carbon back in. And I think thats one of the few solutions that we have really for the climate problem is that we can put carbon in the soil, and we can recharge this system and doing that would take it out of the air and make itmore healthy.Soits really a win-win.

Excerpt from:
Seven Stories of Regeneration | Tufts Now - Tufts Now

Read More...

I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic – PRNewswire

Thursday, December 17th, 2020

Avery Therapeutics is projected to be one of the first companies in the US to seek approval for a clinical trial using iPSC-derived technology for heart failure. The goal of this collaboration is to develop a new off-the-shelf treatment to improve the quality of life of patients suffering from heart failure, a debilitating disease that affects tens of millions of people worldwide.

The iPSCs are manufactured at I Peace's state-of-the-art GMP facility in Kyoto, Japan, under comprehensive validation programs of the facility, equipment, and processes including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution. I Peace has obtained a US-based independent institutional review board (IRB) approval for its process of donor sourcing for commercial-use iPSCs. The facility is designed to be PMDA and USFDA compliant.

As Avery Therapeutics expects to expand the application of its regenerative medicine technology to various types of heart diseases and beyond, iPSCs are the key enabling technology for quality and future scalability. This agreement provides a solid foundation to improve the welfare of those suffering from diseases through advancement of tissue-engineered therapeutics.

"We are thrilled to announce this collaboration with I Peace. It is a big step forward in the development of novel cell-based therapeutics for unmet medical needs. Through this collaboration, I Peace brings deep iPSC development and manufacturing expertise to enable Avery's proprietary MyCardia cell delivery platform technology. Together we hope to positively impact millions of patients worldwide in the near future," Said Jordan Lancaster, PhD, Avery Therapeutics' CEO.

This agreement reflects an innovative collaboration involving multiple locations internationally and marks a significant milestone for both I Peace, Inc. and Avery Therapeutics to pursue one of the first US clinical trials using iPSC technology in the area of heart diseases. Koji Tanabe, PhD, founder and CEO of I Peace stated: "By combining I Peace's proprietary clinical grade iPSC technology and Avery's tissue engineering technology, we can bring the regenerative medicine dream closer to reality. We are very excited by Avery's technology and look forward to continue working together."

About I Peace, Inc

I Peace, Inc. is a global supplier of clinical and research grade iPSCs. It was founded in 2015 in Palo Alto, California, USA by Dr. Tanabe, who earned his doctorate at Kyoto University under Nobel laureate Dr. Shinya Yamanaka. I Peace's mission is to alleviate the suffering of diseased patients and help healthy people maintain a high quality of life by making cell therapy accessible to all. I Peace's state-of-the-art GMP facility and proprietary manufacturing platform enables the fully-automated mass production of discrete iPSCs from multiple donors in a single room. Increasing the available number of clinical-grade iPSC lines allows I Peace customers to take differentiation propensity into account to select the most appropriate iPSC line for their clinical research at significantly reduced cost. I Peace aims to create iPSCs for every individual that become their stem cell for life.

Founder, CEO: Koji TanabeSince: 2015Head Quarter: Palo Alto, CaliforniaJapan subsidiary: I Peace, Ltd. (Kyoto, Japan)Cell Manufacturing Facility: Kyoto, JapanWeb: https://www.ipeace.com

About Avery Therapeutics

Avery Therapeutics is a company developing advanced therapies for patients suffering from cardiovascular diseases. Avery's lead candidate is an allogeneic tissue engineered cardiac graft, MyCardia in development for treatment of chronic heart failure. Using Avery's proprietary manufacturing process MyCardia can be manufactured at scale, cryopreserved, and shipped ready to use. Avery is leveraging its proprietary tissue platform to pursue other cardiovascular indications. For more information visit: AveryThera.com. Follow Avery Therapeutics on LinkedInand Twitter.Since: 2016Headquarter: Tucson, AZWebsite: https://www.AveryThera.com

SOURCE I Peace, Inc.

Read this article:
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire

Read More...

Latest Study explores the Regenerative Medicine Products Market Witness Highest – GroundAlerts.com

Thursday, December 17th, 2020

Global Regenerative Medicine Products Market analysis report speaks about the manufacturing process. Global Regenerative Medicine Products market report analyses the market growth, trends, overview & forecast to 2026.The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies.

The research study on Regenerative Medicine Products market boasts of a detailed analysis of this industry vertical, alongside a robust gist of its segmentation. The report is inclusive of a highly viable analysis of the current status of the Regenerative Medicine Products market as well as the market size in terms of the valuation and the volume. Additionally, the research study encompasses a collective summary of vital information with regards to the regional terrain and the companies that have established their stance across this business space.

Request a sample Report of Regenerative Medicine Products Market at:https://www.marketstudyreport.com/request-a-sample/3077558?utm_source=groundalerts.com&utm_medium=SK

Enumerating a rough coverage of the Regenerative Medicine Products market research report:

An in-depth portrayal of the regional landscape of the Regenerative Medicine Products market:

A detailed cover-up of the competitive terrain of the Regenerative Medicine Products market:

Ask for Discount on Regenerative Medicine Products Market Report at:https://www.marketstudyreport.com/check-for-discount/3077558?utm_source=groundalerts.com&utm_medium=SK

A few other takeaways from the research study on the Regenerative Medicine Products market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-regenerative-medicine-products-market-outlook-2021

Related Reports:

1. Global Small Animal Imaging Reagents Market Outlook 2021Read More: https://www.marketstudyreport.com/reports/global-small-animal-imaging-reagents-market-outlook-2021

2. Global Antioxidant Vitamins Market Outlook 2021Read More: https://www.marketstudyreport.com/reports/global-antioxidant-vitamins-market-outlook-2021

Related Report : https://www.marketwatch.com/press-release/brand-licensing-market-statistics-2020-2025-share-forecasts-trends-growth-drivers-2020-12-15

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See original here:
Latest Study explores the Regenerative Medicine Products Market Witness Highest - GroundAlerts.com

Read More...

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules – PRNewswire

Thursday, December 17th, 2020

HELSINKI, Dec. 17, 2020 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis' CDNF and xCDNF therapies (Parkinson's disease) using Nanoform's proprietary biological nanoparticle technology.

The planned and non-exclusive collaboration is intended to assess the utility of Nanoform's latest platform technology for biologic drugs. The technology was recently launched, post filing of a provisional patent application with the US Patent Office, to enable production of biological nanoparticles as small as 50 nm.

Subject to finalizing definitive agreements, Nanoform will in this partnership carry out, for compensation on standard commercial terms, two Proof of Concept studies on Herantis' CDNF and xCDNF molecules leveraging Nanoform's novel platform and its in-house formulation expertise. The goal of the planned collaboration is to increase the probability of success for enhanced BBB (Blood-Brain-Barrier) penetration in the nasal drug delivery route for CDNF and x-CDNF.

Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis.

"We are delighted to support Herantis Pharma in their development programs in CDNF and latest generation xCDNF molecules. Completing this deal validates the strong market interest in, and potential value that, Nanoform's platform technologies can add to pharmaceutical development programs and to the patient" said Prof. Edward Hggstrm, CEO of Nanoform.

"We look forward to working together to enhance and enable superior formulations of the pioneering new drugs we have developed. Nanoform's technologies show much promise for enhanced drug delivery applications in this complex and challenging field. It is our hope that this will open up new possibilities for improving the lives of patients with Parkinson's and other related diseases. We value the opportunity to enter into collaboration with Nanoform and look forward to what the future brings." said Dr. Craig Cook, CEO, Herantis Pharma.

For further information, please contact:

Prof. Edward Hggstrm, CEO

[emailprotected]/ +358 29 415 0684

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[emailprotected]/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

For more information please visit http://www.nanoform.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. The Herantis programs are potentially disease modifying that treat the cause as well as symptoms of disease, and bring the innovation necessary to provide further treatment options in underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit https://www.herantis.com

Forward-Looking Statements (Nanoform)

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on May 22, 2020) in connection with Nanoform's initial public offering (the "Prospectus") under "Risk Factors" and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-and-herantis-partner-to-look-for-opportunities-to-enhance-bbb-penetration-of-cdnf-and-xcdnf,c3257538

The following files are available for download:

SOURCE Nanoform

Read the original post:
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules - PRNewswire

Read More...

New Research Study Shows Efficacy of Sustained Acoustic Medicine as Add-on Therapy in Treating Sport-Related Injuries and Returning Athletes to Play -…

Thursday, December 17th, 2020

TRUMBULL, Conn., Dec. 15, 2020 /PRNewswire/ --ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device, was recently evaluated in a research study published in the Global Journal of Orthopedics Research, which measured the effectiveness of SAM treatment to reduce pain and improve function in athletes in conjunction with traditional therapies following sports-related musculoskeletal injuries. According to the study, the data "confirms the effectiveness of the application of SAM ultrasound in reducing pain as adjunct therapy or standalone therapy."

"The study confirms the effectiveness and benefits for home users, both athletes and non-athletes, who have sustained some kind of musculoskeletal injury," according to Dr. George Lewis, Founder and CEO of ZetrOZ. "The cases referenced in the study indicate SAM's ability to penetrate deep into muscle tissue and provide relief from pain and injury with regular treatment, helping accelerate the healing process and decrease the time it takes to recover."

The study included a case series of 18 professional and collegiate athletes who suffered a musculoskeletal, sports-related injury. The athletes were treated with SAM as supplementary therapy at a specified sports medicine rehabilitation clinic. Regular treatments resulted in 'reduced pain and improved function across numerous muscles, ligament, and tendon conditions.' Most of the athletes in the study were able to return to normal activity, including sports, during their treatment period.

The athletes in the study had previously undergone surgeries or were being considered for surgery. By utilizing sustained acoustic medicine as a long-duration continuous ultrasound therapy, users can accelerate the natural process of healing by inhibiting inflammation, increase the rate of tissue regeneration, angiogenesis, and nutrient exchange.

To read the study in full, visit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544191/.

To learn more about ZetrOZ Systems and the company's SAM line of products, visitsamrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more atzetroz.comandsamrecover.com.

Media Contact

LedoraBrown

[emailprotected]

Related Images

real-world-outcomes-study-on-sam.jpg Real-world outcomes study on SAM wearable ultrasound treatment published in the Global Journal of Orthopedic Research 2020

SOURCE ZetrOZ Systems

See more here:
New Research Study Shows Efficacy of Sustained Acoustic Medicine as Add-on Therapy in Treating Sport-Related Injuries and Returning Athletes to Play -...

Read More...

Texas A&M Professor Awarded Department Of Defense Grant For Gulf War Illness Research – Texas A&M University Today

Thursday, December 17th, 2020

Ashok Shetty is a professor in the Department of Molecular and Cellular Medicine and associate director for the Institute for Regenerative Medicine at the Texas A&M University College of Medicine.

Texas A&M Health Science Center

Thousands of American troops who were deployed in theFirst Gulf War were exposed to a variety of chemicals that resulted in psychological and physiological symptoms that health experts call Gulf War illness (GWI), previously called Gulf War syndrome.

Ashok Shetty, professor in the Department of Molecular and Cellular Medicineand associate director for the Institute for Regenerative Medicine at theTexas A&M University College of Medicine, has teamed up withKimberly Sullivan from the Boston University School of Public Health and Dr. Nancy Klimas Nova Southeastern University to investigate the extent and mechanisms of brain inflammation in veterans with GWI through a liquid biopsy approach. Their research efforts are being funded by a $1 million grant from the Department of Defense(DOD) over a three-year period.

The condition is characterized by a collection of unexplained chronic symptoms that can include gastrointestinal problems and dermatitis(a skin disorder) or central nervous system problems such ascognitive dysfunction, neuroinflammation, memory problems and depression.Nearly 30% of Gulf War veterans suffer from chronic GWI.Currently, the mechanisms underlying these persistent issues are unknown.

Shettysearlier studies on GWIfocused on theanimal model of GWI, recreating the conditions and chemicals veterans were exposed to during the war. He found that the animal models developed cognitive problems and had increased behavior that was associated with inflammation in the brain. His studies showed that the neuroinflammation in the brains of the animal models was progressive and had gotten worse over time, which explains why GWI is still prevalent in Gulf War veterans 30 years after the war.

Compared to an animal model approach, studying the brain in veterans with GWI is difficult. Therefore, most research with humans has been done through blood sampling, but its difficult to see if the results actually reflected what was happening in the brain. As a result, Shetty developed a liquid biopsy approach, which involves the characterization of the composition of brain-derived extracellular vesicles in the blood.

Shetty and his team will use this liquid biopsy approach to study neuroinflammation in the blood of Gulf War veterans beginning in early 2021.

The Sullivan and Klimas laboratories will collect blood samples of 50 veterans with GWI (patients) and 50 veterans without GWI (controls). Once the blood samples are collected, they will send the samples to Shettys laboratory. Shetty will then use the blood samples to isolate the extracellular vesicles (EV) membrane-enclosed nanosized vesicles that carry cargo such as proteins, lipids and micro-RNAs that come from the brain.

Once the extracellular vesicles are isolated, he will classify each one as a neuron-derived extracellular vesicle (NDEVs) or an astrocyte-derived extracellular vesicle (ADEVs) using a specific tagging technology. Then, Shetty will examine the cargo in the NDEVs and ADEVs, particularlyproinflammatory mediatorsand microRNAs using biochemical assays and RNA sequencing.

Because the composition of EVs reflects the physiological or pathological state of cells from which they are derived at the time of secretion, analysis of EVs derived from specific brain cells in the blood would help in the identification of biomarkers linked to chronic brain impairments, Shetty said.

What this approach means is by just looking at the vesicles, one can tell what is going on in the brain, even the brain cannot be directly studies. This technique of isolating extracellular vesicles was developed by Shetty in 2019, when he used an animal model approach.

Whatever is happening in the brain can be determined by characterizing brain-derived vesicles in the blood, Shetty said. It can be neuron-derived vesicles and astrocyte-derived vesicles, so this project is about that. But now, instead of animal models, we are studying actual veterans. From this human study, we can identify the extent of neuroinflammation in veterans.

Ultimately, this study will likely provide evidence as to why GWI is worse for some veterans compared to others, help diagnose the extent of brain inflammation in veterans with GWI and help determine whether GWI puts veterans at a higher risk for developing other neurological diseases.

The approach is also efficient in future clinical trials for monitoring the remission or progression of brain inflammation with apt treatment strategies, Shetty said.

Read more here:
Texas A&M Professor Awarded Department Of Defense Grant For Gulf War Illness Research - Texas A&M University Today

Read More...

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV – GlobeNewswire

Thursday, December 17th, 2020

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation, said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.

The grant builds upon CRISPR Therapeutics proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

See the original post here:
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire

Read More...

Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report – Focus on Latest Advancements for Chronic Pain…

Thursday, December 17th, 2020

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies 2020" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent innovations in digital health, microbiome, and flu vaccines technologies. The TOE also provides insights across latest advancements for chronic pain management and COVID-19 testing.

The TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/v6l8dq

See the article here:
Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report - Focus on Latest Advancements for Chronic Pain...

Read More...

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,…

Thursday, December 17th, 2020

New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p05995354/?utm_source=GNW However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORTThe 3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030 report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:Brigitte Angres (Co-founder, Cellendes)Bill Anderson (President and CEO, Synthecon)Anonymous (President and CEO, Anonymous)Anonymous (Co-founder and Vice President, Anonymous)Scott Brush (Vice President, BRTI Life Sciences)Malcolm Wilkinson (Managing Director, Kirkstall)Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)Tanya Yankelevich (Director, Xylyx Bio)Jens Kelm (Chief Scientific Officer, InSphero)Walter Tinganelli (Group Leader, GSI)Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information includeAnnual reportsInvestor presentationsSEC filingsIndustry databasesNews releases from company websitesGovernment policy documentsIndustry analysts views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWEREDWho are the leading industry players engaged in the development of 3D cell culture products?What are the most popular 3D cell culture products?What are the different applications for which 3D cell culture products are currently being developed?What are the key factors that are likely to influence the evolution of this market?What is the trend of capital investments in the 3D cell culture systems market?Which partnership models are commonly adopted by stakeholders in this industry?How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?How is the current and future opportunity likely to be distributed across key market segments?What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05995354/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,...

Read More...

Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -…

Thursday, December 17th, 2020

Pune, India, Dec. 14, 2020 (GLOBE NEWSWIRE) -- The report mentions that the Gene Therapy Market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period. The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

KEY INDUSTRY DEVELOPMENTS:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243

Increasing Innovations & Research Activities to Boost Growth

The U.S Food and Drug Administration (FDA) stated that it is expecting to receive more than 200 applications of this therapy by the end of 2020. This showcases that the rising number of research studies and innovations in this field would affect the gene therapy market growth positively in the near future. In North America, almost 208 companies are currently operating in this market. In addition to this, the Alliance for Regenerative Medicine declared that as of 2018, approximately 259 potential drug candidates are under Phase I clinical trials across the globe.

However, the outbreak of the COVID-19 pandemic is presently impacting the field of research. According to the director of the Office of Tissues and Advanced Therapy (FDA) named Wilson Brayan, nowadays the officials are prioritizing only those drugs that are associated with coronavirus.

To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243

The U.S. to Dominate Owing to Presence of Favorable Policies

In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

Besides, the presence of favorable reimbursement policies and guidelines would also help in propelling the market growth here. As this type of treatment is not legal in several developing nations, industry giants are emphasizing on the U.S. for launching their products.

Europe, on the other hand, is anticipated to grow significantly backed by the adoption of unique treatment options. Asia Pacific is set to hold a comparatively lower share on account of the decreasing usage of gene therapy because of its expensive nature.

Quick Buy - Gene Therapy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100243

List of Key Players operating in Gene Therapy Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/gene-therapy-market-100243

Global Gene Therapy Market Segmentations:

By Application

Oncology

Neurology

Others

By Vector Type

Viral

Non-viral

By Distribution Channel

Hospitals

Clinics

Others

By Geography

U.S.

Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, and Rest of Asia- Pacific)

Rest of World

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/gene-therapy-market-100243

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

India Peritoneal Dialysis Market Share & Industry Analysis, By Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), Automated Peritoneal Dialysis (APD)), By Product (Devices (Cyclers/Machines), PD Solutions/Fluids, PD Sets, Catheters) Forecast, 2019-2025

Guidewire Market Share & Industry Analysis, By Product (Coronary Guidewire, Peripheral Guidewire, Urology Guidewire, Neurovascular Guidewire, and Others) By Material (Nitinol, Stainless Steel, and Others) By Coating (Coated and Non-Coated) By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2026

India Insulin Pumps Market Share & Industry Analysis, By Product (Insulin Pumps (Tethered Pumps and Patch Pumps) and Consumables (Reservoirs, Infusion Sets, and Others) and Region Forecast, 2019-2025

Lactose Market Share Trends & Industry Analysis, By Purity (Crude Lactose, Edible Lactose, and Refined-edible Grade Lactose), By Color (Yellow Lactose, Pale-yellow to White Lactose, and White Lactose), By Applications (Food, Feed, Infant Formula, and Pharmaceuticals), and Regional Forecast, 2019-2026

Contact Lenses Market Share & Industry Analysis, By Modality (Reusable and Disposable), By Design (Toric, Multi-focal, and Spherical), By Distribution Channel (Retail Stores, Online Stores, and Ophthalmlogists), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-gene-therapy-market-10136

Go here to see the original:
Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -...

Read More...

REGENCare Life Magazine Interviews NFL’s 3X Super Bowl Champion, Rob Gronkowski, and Atlanta’s Anti-Aging Expert, Dr. Richard Ambrozic, Regarding…

Thursday, December 17th, 2020

I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal.

ATLANTA (PRWEB) December 14, 2020

Announcing the launch of REGENCare Life Magazine. Published in conjunction with Local Umbrellas C4 Lead Machine, the inaugural issue features interviews with Rob Gronkowski, the Atlanta Braves legendary Ryan Klesko and Atlantas Celebrity Anti-Aging Expert, Dr. Richard Ambrozic (@drrick), regarding the very latest in Regenerative Therapies designed to renew and restore function in the body. The magazines inaugural edition features stories and testimonials from professional athletes and many other patients benefiting from these Allograft Regenerative Therapies.

REGENCare Life Magazine features an interview with Tampa Bay Buccaneers tight end Rob Gronkowski by C. Christie Craig. (See Interview below.)

The highs and lows of football players are well known. When you are young, strong, and focused, the game has no limits. But the body can only take so many hits; there is a huge price to pay for years of playing hard on the field. Rob Gronk Gronkowski, one of the NFLs all-time greatest tight ends, knows this all too well. In 2019, Rob announced his retirement from the New England Patriots, needing a break to focus on his health and well-being. At 30 years old, he had an extraordinary run, making his mark in football history. Fans were devastated and Rob was hurting.

Today, after a multitude of various regenerative treatments throughout last year, Robs new nickname is Mr. Recovery. His body and mind are healed, and he has a fresh new deal with the Tampa Bay Buccaneers. The best part is hes going to share his most amazing discovery. In fact, he is ready to shout it out to all who will listen. Thats good news, because when it comes to overcoming pain, hes someone we should listen to carefully. Not only is he an amazing athlete; he is also a successful businessman and philanthropist.

Gronk was always well-loved by fans and teammates, and many thought his career was over. But he was not the type to give up, and he decided that pain was not going to mean the end of his story. How he eliminated it and got back on the field is an inspiring story for all of us. In this interview, Rob shares how he found his fire and returned to the NFL through regenerative care treatments. Here is the incredible story of his journey back to health and wellness in his own words.

Question: I am here with the greatest tight end in NFL history who now calls himself Mr. Recovery. After a litany of injuries, you are coming out of retirement this year and making your comeback with the Tampa Bay Buccaneers. How did this all happen?

Gronk: Thank you! I am super excited, super pumped up. I feel so good, you know. I let my body heal and recover. Ive been playing football for fifteen plus years, plus along with other sports, and with all this action Ive seen, my body just needed a little rest. I had to investigate and find connections to heal. Dr. Rick turned everything around for me. Its a full-time job as an athlete. Athletes dont just show up. We have to take care of our bodies and find solutions that work. The recovery is cake with Dr. Rick.

Question: Your journey back to health is unprecedented. Few NFL players return to action after retiring like you did. Allografts are the new buzz words for lasting recovery. Is this the type of therapy and injections you received from Dr. Rick at REGENCare?

Gronk: Yes, I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal. This treatment is exactly what I needed. I am sharing this information with others because this treatment isnt only for professional athletes like me. It can help everyone!

Question: How is your healing different with REGENCare Therapy compared to traditional treatment?

Gronk: In your early twenties you really dont get into the treatment. You just do the basics and the bare minimum. But as you get older, you have to treat your body more, you need to find new ways, and thats what Ive been doing over the last few years. Aside from the allografts, there are so many options at REGENCare. Im getting massages, doing vitamin IVs, and lying in the hyperbaric chamber. This chamber fills my body up with clean, pure oxygen. Without oxygen in your body, you are not going to survive! Its just spectacular when you can get more and more oxygen into your system. Your muscle tissues start feeling pliable and loose and it targets all those nagging injuries to help them heal. It is my favorite treatment because I get a nap and I am getting rejuvenated at the same time by all the oxygen. Its great. We also do a couple other treatments to help with recovery, stress management, improving sleep and diet.

Question: Do REGENCare Therapy treatments make a difference in how fast you recover and heal?

Gronk: I definitely feel a big difference. Back in the day, I would just let my body heal naturally, and when I say naturally, I would just do the bare minimum. I would be running around on it. I would be partying on the injury while it was trying to heal. But I was so young then, and I could get away with it. But now that I want to continue my career, and Im older, I learned that I needed to start adapting. You got to adapt to the change, you got to start adapting to your body. And you know, finding that adaptation includes a whole spectrum of healing treatments from allografts and finally, to proper nutrition.

Question: How does your focused mindset play a role in your healing? Is it an importantpart of your treatment process?

Gronk: Yeah, definitely! Some people can be telling you to do this, and you just got to stick with your gut. You got to stick with your heart, knowing what is best for your body. To know that, you have to go through a lot of experiences. Ive tried many, many things, and some do work for me. I focus on all the natural treatments that you could do for yourself. I find the best ones that suit me and enjoy em while doing em.

What would you tell your friends and teammates who are suffering from chronic pain and injuries about these regenerative treatments?

Gronk: Just get started on it now! The longer you wait, the harder it is going to be to heal that injury and nagging pain. The longer you wait, it gets more settled into your brain that you have that nagging pain. So hop on it ASAP, get moving, get cruising on it, find some good workouts, strengthen your core tight, and start small. Thats where it begins. You dont got to go big at all. Just start small and make little changes.

Question: So whats next for you? You have an exciting season with Tampa Bay, what are some of the things that youre doing to prepare?

Gronk: You know, Im just hanging out! Throwing footballs, doing football workouts, doing band workouts, doing some strength workouts, just doing it all at high speed. Its a lot of expectations for sure. Just have to go in and be a consistent player and youre just ready to go. Im just excited to get back out into the field and play some football and help out the team.

Question: If you were to leave a legacy behind, what would it be?

Gronk: Just working hard, being the best teammate that I can be and doing the best that I can to help out the team. Now that Dr. Rick has helped me to recover, I can achieve this and more.

Get your copy & learn more about how Allograft Regenerative Therapies can help you at https://www.REGENCare.life.

Regenerative Medicine Treatments at REGENCare

Our regenerative medicine treatments utilize regenerative medicine to encourage tissue healing throughout affected areas. REGENCare utilizes regenerative medicine allografts, Pulsed Electro-Magnetic Field technology to stimulate and exercise the cells and address cellular dysfunction and support overall wellness, Shockwave Therapy to promote regeneration and repair of the bones, tendons and other soft tissues, Georgias first PRISM Light Pod which uses specific wavelengths of light that pass through layers of skin and interact within the body to stimulate regrowth and repair, IV Hydration which provides the vitamins, minerals, and amino acids your body needs, Hyperbaric Oxygen Therapy which can significantly increase the concentration of circulating progenitor cells within the peripheral circulation system, and more. We may be able to help in orthopedic conditions, like osteoarthritis, meniscus and cartilage tears, tendinitis, joints and back pain, inflammation, hair restoration, skin rejuvenation and anti-aging treatments.

About Richard Ambrozic, MD, Founder and CEO, REGENCare:

Dr. Ambrozic (@drrick) earned his MD from the University of Alberta. He completed a residency in health prevention and family medicine at the University of British Columbia and has completed an anti-aging fellowship from the University of South Florida. The American College of Sports Medicine, American Academy of Anti-Aging Medicine, American Medical Association, Medical Association of Georgia, and the American Society for Laser Medicine and Surgery. He is a member of the Harvard Medical School Postgraduate Association. He is an expert in Allografts, Lasers, and Anti-Aging.

Dr. Ambrozic is the founder of REGENCare, with locations in Buckhead, Atlanta, Jupiter/Palm Beach Florida, and soon around the world. He treats professional athletes, celebrities, and patients from all walks of life interested in regenerative and anti-aging medicine. Healing the body naturally and safely, without pills and unnecessary surgery is most important. Dr. Ambrozic has traveled the world to bring the very latest and state-of-the-art regenerative medicine protocols, technology, and procedures to his clinics.

Please call our office to book your free consultation so Dr. Ambrozic and the REGENCare team can plot your course to better health.

Call 678-430-3039 or email at appointment@regencare.life.

Please visit our website at https://www.REGENCare.life

Please visit our Social Media:

https://www.instagram.com/drrick/https://www.facebook.com/richard.ambrozichttps://www.linkedin.com/in/dr-richard-ambrozic-70206124/

Contact:

REGENCareDr. Richard Ambrozic (@drrick)Office Phone: 678-430-3039 Email: appointment@regencare.lifeAddress: 240 Pharr Rd. Atlanta, GA 30305 (Buckhead Village)

Read the original post:
REGENCare Life Magazine Interviews NFL's 3X Super Bowl Champion, Rob Gronkowski, and Atlanta's Anti-Aging Expert, Dr. Richard Ambrozic, Regarding...

Read More...

Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine – Newswise

Friday, December 4th, 2020

Newswise DALLAS Dec. 3, 2020 A team led by UT Southwestern has derived a new intermediate embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing nave embryonic stem cells (those about four days post-fertilization in mice) and primed epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, theres been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named XPSCs from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

These XPSCs have enormous potential. Our study helps open the door to each of these possibilities, says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep nave PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for nave PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF- pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-.

Aiming for the preferred environment for XPSC derivation, Wu and his colleagues placed cells from early mouse embryos into cultures containing chemicals and growth factors that activate all three pathways. These lab-grown cells were extremely stable in culture and able to multiply without developing any further for approximately two years.

Additional experiments showed that these cells met the expectations researchers have long strived to meet of contributing to chimeras and directly differentiating into primordial germ cells. Wu and his colleagues made intraspecies chimeras of mice using cells derived from mice with different coat colors by injecting the cells into early mouse embryos. They also tracked the contributions of the XPSCs by tagging the cells with a fluorescent protein and then identifying them throughout the resulting offsprings body.

Wus team made interspecies chimeras by injecting horse XPSCs into early mouse embryos and allowing the embryos to develop in mice for several days. Surprisingly, although horses have a comparatively long gestational period nearly a year the researchers found that these foreign cells had contributed to mouse organ development, indicating that signals from the mouse cells determine organ developmental timelines.

Like XPSCs from other species, the human cells showed that they were capable of differentiating into a variety of tissues if culture conditions allowed them to progress in development, as well as directly form primordial germ cells in a dish.

Other UTSW researchers who contributed to this study include Leqian Yu, Yulei Wei, Carlos A. Pinzon Arteaga, Masahiro Sakurai, Daniel A. Schmitz, Canbin Zheng, and Emily D. Ballard. Yu and Wu are inventors on a patent application arising from this work.

This study was funded by the Cancer Prevention and Research Institute of Texas (CPRIT No. RR170076), the Hamon Center for Regenerative Science and Medicine, the Guangdong Provincial Key Laboratory of Genome Read and Write (No. 2017B030301011), and the Asahi Glass Foundation.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 23 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,500 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 3 million outpatient visits a year.

Read the original:
Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine - Newswise

Read More...

Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra’s Latest Product Offerings to…

Friday, December 4th, 2020

Pune, India, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The global regenerative medicine market size is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. The market was valued at US$ 23,841.5 Million in 2018. Fortune Business Insights states that the market will reach US$ 151,949.5 Million by the end of 2026, thereby exhibiting a CAGR of 26.1%. North America generated maximum revenue of US$ 9,128.2 Million in 2018 and is expected to dominate the global regenerative medicine market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America.

Key Industry Developments:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Increasing Investment in R&D of Regenerative Medicine to Enable Growth

The growing investment in research and development of regenerative medicine has made a significant contribution to the growth of the global market. The increasing investment from private as well as government organizations has had a positive impact on the global market. IN March 2018, SanBio collaborated with Hitachi Chemical Advanced Therapeutics Solutions for developing regenerative medicine across a wide range of applications.

Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines.

Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine Luxturna. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases.

Integra LifeSciences Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer Thin.

Fortune Business Insights some of the leading companies that have made significant growth contributions to the global market. Besides this, the report identifies some of the attractive business strategies that have been adopted by renowned companies in the world.

Quick Buy - Regenerative Medicine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100970

List of the leading companies that are operating in the Regenerative Medicine Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/regenerative-medicine-market-100970

Global Regenerative Medicine Market Segmentation:

By Product

Cell Therapy

Gene Therapy

Tissue Engineering

Platelet Rich Plasma

By Application

Orthopedics

Wound Care

Oncology

Others

By Distribution Channel

Hospitals

Clinics

Others

By Geography

North America (USA and Canada)

Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

Latin America (Brazil, Mexico and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/regenerative-medicine-market-100970

SECONDARY DATA SOURCES THAT WE REFER TO:

Have a Look at Related Reports:

Bovine Lactoferrin Market Share Trends & Industry Analysis, By Product (Spray-dried, and Freeze-dried), By Application (Infant Formula, Pharmaceuticals, Dietary Supplements, Food, and Others), and Regional Forecast, 2019-2026

Knee Replacement Market Share & Industry Analysis, By Procedure (Total Knee Arthroplasty, Partial Knee Arthroplasty, and Revision Arthroplasty) By Implant Type (Fixed Bearing, Mobile Bearing, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2019-2026

Electrophysiology Devices Market Share & Industry Analysis, By Type (Ablation Catheters, Diagnostic Catheters, Mapping Systems, Accessories & Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, and Others), By End User (Hospitals & ASCs, and Specialty Clinics & Diagnostic Centers), and Regional Forecast, 2019-2026

Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Prefilled Syringes Market Share & Industry Analysis, By Material (Glass and Plastic) By Closing System (Staked Needle System, Luer Cone System, and Luer Lock Form System) By Product (Complete Syringe Set and Components & Accessories) By Design (Double-chamber, Multiple-chamber, and Single-chamber) By End-user (Pharmaceutical & Biotechnology Companies, Contract Research & Manufacturing Organizations, and Others) and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/regenerative-medicine-market-9183

Read more from the original source:
Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra's Latest Product Offerings to...

Read More...

Rare-disease foundation backs regenerative research – OutSourcing-Pharma.com

Friday, December 4th, 2020

CureDuchenne is a global nonprofit honed in on discovering a cure for Duchenne muscular dystrophy (DMD). Its funding arm, CureDuchenne Ventures, is investing in regenerative medicine firm Mesentech, as part of a joint funding collaboration with the Charles H Hood Foundation (which seeks to advance early-stage research for pediatric conditions).

CureDuchenne Ventures, the funding arm of CureDuchenne (a nonprofit aimed at discovering a cure for Duchenne muscular dystrophy) is investing in Mesentech Inc., a regenerative medicine company with a prodrug platform that selectively delivers therapeutics to bone. The project is part of a new joint funding collaboration with the Charles H. Hood Foundation (CHF), which seeks to advance early-stage research for pediatric conditions.

Lianna Orlando, CureDuchennes senior director of research, told Outsourcing-Pharma that bone fractures and quality of life are the top two main outcome measures identified by people with DMD.

Individuals with Duchenne are at a high risk for osteoporosis for multiple reasons that include reduced weight-bearing activity (which normally drives development of strong and dense bones), as well as a side-effect of glucocorticoid therapy, and from the effect of the chronic inflammatory response seen in dystrophin-deficient muscles, she said. Fractures in the vertebral bones of the spine are seen in up to 30% of boys with Duchenne, and in addition to being very painful may lead to spine deformity; fractures in the long bones in the arm or the leg are common, and in many cases lead to permanent loss of ambulation.

Whats more, she said, bone fractures can lead to additional complications.

Long bone fractures can release fat emboli into the bloodstream, which can obstruct blood flow in critical places, including the lungsmost often the lungs. Although rare, fat embolism syndrome is a particularly serious complication of bone fractures in Duchenne; in the most severe cases, fat embolisms can lead to death, Orlando told OSP.

The CureDuchenne investment supports Mesentechs lead program, MES-1007, into clinical development and its evaluation in DMD. There are currently no approved therapies for bone wastage for individuals affected by DMD.

Debra Miller, founder and CEO of CureDuchenne, said the investment and collaboration hold the potential to increase the groups impact.

Addressing bone morbidities that contribute to the loss of ambulation could significantly add quality of life to everyone affected by Duchenne, said Miller.

In addition to providing Mesentech with funding, CureDuchenne intends to play an active role in advancing the prodrug technology platform for DMD. Additionally, CureDuchenne chief scientific officer Michael Kelly will join Mesentechs scientific advisory board.

See more here:
Rare-disease foundation backs regenerative research - OutSourcing-Pharma.com

Read More...

Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai – Newswise

Friday, December 4th, 2020

Newswise LOS ANGELES (Dec. 1, 2020) -- Internationally recognized hematologist John P. Chute, MD, has been selected to direct the Division of Hematology and Cellular Therapy in the Department of Medicine at Cedars-Sinai Cancer. The physician-scientist also will serve as director of the Center for Myelodysplastic Diseases Research and associate director of the Board of Governors Regenerative Medicine Institute in the Department of Biomedical Sciences. Chute assumed his new post Nov. 23.

The selection of Chute, following a national search, reflects the importance of his pioneering research in blood-forming stem cells called hematopoietic stem cells, which can self-renew and generate all cell types found in the blood and immune system. Over the past decade, Chute's lab has discovered several growth factors produced by the cells that line the walls of blood vessels; they play a critical role in blood-forming stem cell regeneration.

"Dr. Chute is an exceptional addition to our faculty," saidDanTheodorescu, MD, PhD, director ofCedars-Sinai Cancer. "His international reputation as a physician-scientist who has made major contributions to stem cell and hematopoietic cell biologywill greatly contribute to positioning the newly created Division of Hematology and Cell Therapy as one of the best in the nation, while providing Cedars-Sinai Cancer patients with exciting new options for the treatment of blood malignancies."

In addition to his hematopoietic stem cell research, Chute said he looks forward to expanding Cedars-Sinai's CAR T-cell research and therapy. He describes the immune-boosting therapeutic as "transformative" for patients with advanced non-Hodgkinlymphoma,childhood acute lymphoblastic leukemiaand potentially several additional blood cancers.

CAR T-cell therapy is a type of immunotherapy in which patients' own immune cells, called T cells, are collected from their blood, and then an artificial receptor chimeric antigen receptor, or CAR is added to the cells' surface. The receptor enables the modified cells to specifically eradicate cancer cells. The cells are infused back into a patient's body intravenously, where they multiply and attack tumor cells.

"CAR T therapy has become an important treatment option for so many patients with advanced cancer who had no options before," Chute said. "That's what makes CAR T therapy so exciting."

Chute joins Cedars-Sinai from the David Geffen School of Medicine at the UCLA, where he was a professor of Medicine and Radiation Oncology in the Division of Hematology/Oncology and an investigator in the Broad Stem Cell Research Center.

Chute earned his medical degree at Georgetown University. He completed his residency in internal medicine and fellowship in Hematology/Oncology at the National Naval Medical Center. He completed his research training at the National Cancer Institute and the Naval Medical Research Institute.

"I'm excited to join the Cedars-Sinai Cancer faculty because of the opportunity to collaborate with the world-class scientists and top-tier physicians at the cancer center," Chute said. "Cedars-Sinai has always been a leading medical center and is deeply committed to basic and translational research, while also growing the hematology and cellular therapy specialties. I'm eager to play a leading role in that growth."

Clickhereto read more from the Cedars-Sinai Newsroom.

Excerpt from:
Hematologist/Stem Cell Biologist to Direct Hematology and Cellular Therapy at Cedars-Sinai - Newswise

Read More...

How biotech startup Seragen is reworking infertility treatments with regenerative therapies – YourStory

Friday, December 4th, 2020

BABIES!

Most people love babies and want a few at some point in their life. But for about 30 million infertile couples in India, alone, babies are an out-of-reach pipe dream.

When Vasanthi Palanivel, a biotech scientist with two decades of experience, saw her friend, Srinivas Chari and his wife undergoing issues with conceiving a baby - and the immense grief that failed treatments caused - she decided to do something about it.

Vasanthis work in the biotech space focused specifically on tissue engineering and stem cell-based treatments, and she decided to use that expertise to develop a regenerative medicine-based infertility treatment, which she claims is better than most traditional treatments available today.

Fertility treatments are expensive - around Rs 1 lakh to Rs 1.25 lakh, per cycle, according to price ranges outlined online by leading IVF treatment centres, have low success rates, and, more importantly, are not covered by insurance. Only a percent of the 30 million infertile couples in India seek IVF treatments, and most of them target very specific problems with synthetic solutions, instead of restoring the patients health, holistically.

She says plasma-based treatments offer breakthroughs where traditional medicine has limited scope. Regenerative treatments are also generally safer, fast-acting, and go beyond just treating the symptoms and problem areas - they help restore organs, tissues and muscles to their ideal state so that the body can function as its supposed to.

So far, the startup has raised angel funding from several individual investors, and is open to more investments. Vasanthi, whos also the startups Chief Scientific Officer, says the venture is profitable, and growing at 100 percent, year on year.

Seragen, founded in 2018, treats over 10 conditions related to male and female infertility, including repeated miscarriages, low testosterone, erectile dysfunction, hormonal imbalance and endometriosis, among others.

The startup gets most of its clients via doctor referrals. On a pre-determined date, the patients case history detailing their medical condition, and their blood sample is collected by Seragens laboratory. The scientists then concoct a personalised fertility medicine, specific to the patients condition, and then send it back to the doctor for administering.

Image credit: Shutterstock

The process takes around 45 minutes, and the medication kicks in roughly 48 hours later.

The cost of the treatment is less than 10 percent of current fertility treatments, she adds.

So far, Seragen has treated over 2,000 patients. Its most requested treatments are for ovarian failures and endometrium. Women over 35 form a large part of the startups patient base.

Currently, the firm is piloting an immunology-based protocol with Indira IVF to target miscarriages - and Vasanthi says she hopes to publish encouraging results soon. The company is also working on a treatment to help prevent the death of mothers after they give birth.

Present in several cities in India already, Seragen is aiming to strengthen its presence domestically, as well as internationally. The startup says it will start operating in South Asian countries like Sri Lanka and Seychelles soon.

The startup competes with generic infertility treatment providers, as well as some stem cell-based therapy providers.

The global regenerative market is expected to reach $17.9 billion by 2025, from $8.5 billion in 2020, and growing at a CAGR of 15.9 percent, a Markets and Markets research report showed. Chronic diseases, genetic disorders and cancers, as well as rising investments in regenerative medicine research is expected to drive most of the growth, the research said.

More:
How biotech startup Seragen is reworking infertility treatments with regenerative therapies - YourStory

Read More...

Resolution Therapeutics Announces a 26.6m Series A Financing from Syncona Ltd – PharmiWeb.com

Friday, December 4th, 2020

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

See original here:
Resolution Therapeutics Announces a 26.6m Series A Financing from Syncona Ltd - PharmiWeb.com

Read More...

AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer – Yahoo Finance

Friday, December 4th, 2020

VALENCIA, Calif, and MELBOURNE, Australia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

Kathys extensive healthcare experience and industry insight are a welcome addition to AVITAs leadership team, said Dr. Mike Perry, AVITA Therapeutics Chief Executive Officer. In particular her broad operational experience within Regenerative Medicine will be critically important as we seek to bring our pipeline products through development and into the markets.

Ms. McGee joins AVITA with over 25 years of biopharmaceutical and life sciences experience, most recently serving as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry. Prior to CnA Consulting, Ms. McGee was the Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President of Operations and General Manager, with responsibility for the companys manufacturing operations in La Jolla, CA. She has also held senior Operations leadership roles at Smith and Nephew and Advanced Tissue Sciences. She earned her Bachelor of Science in chemistry and mathematics from University College Galway Ireland, and holds a Masters degree in Business and Management from Webster University.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

Story continues

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

Continued here:
AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer - Yahoo Finance

Read More...

EVerZom Raises 1.1M to Industrialize Its Exosome Biomanufacturing Platform – Business Wire

Friday, December 4th, 2020

PARIS--(BUSINESS WIRE)--EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised 1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022.

Towards the emergence of new therapeutics in regenerative medicine

Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules. They have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure, and liver and kidney diseases, conditions which impact more than 150 million patients worldwide. Exosomes are now considered one of the safest and most promising future regenerative therapy solutions. They are also easy to store and have a low immunogenic profile, thus reinforcing their potential.

Increasingly, academic and industrial players are working on the therapeutic potential of exosomes. The main obstacle to the translation of exosomes into clinical development is industrial manufacturing while maintaining robust quality and reproducibility.

EVerZom's proprietary innovation consists in applying turbulence stimulation on cells to trigger massive exosome release. This approach enables the production of ten times more exosome ten times more rapidly than classical methods. The technology is being developed and already implemented in GMP certified systems, simplifying the clinical transfer.

This technology and the know-how developed around exosomes allows EVerZom to offer a scalable and reproducible exosome production process with robust quality controls. Everzom's internal R&D is continuing its work on the link between the qualification of exosomes and their application potential. EVerZom's ambition is to become the European leader in the bioproduction of exosomes.

"We are delighted with this financing opportunity, which will enable us to industrialize our proprietary technology and meet the growing demand of the exosome market. Our ambition is to foster the emergence of new exosome therapeutic strategies and to make them accessible to the largest possible number of patients as quickly as possible" explains Jeanne Volatron, Co-founder and President of EVerZom. http://www.everzom.com

Excerpt from:
EVerZom Raises 1.1M to Industrialize Its Exosome Biomanufacturing Platform - Business Wire

Read More...

Regenerative Medicine Market to Witness Steady Expansion During 2025 – Murphy’s Hockey Law

Friday, December 4th, 2020

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Regenerative Medicine Market to Witness Steady Expansion During 2025 - Murphy's Hockey Law

Read More...

Page 11234..1020..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick